• 1. Department of Science and Technology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. School of Public Health, Chongqing Medical University, Chongqing 400016, P. R. China;
  • 3. Medical Research and Biometrics Center, National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102308, P. R. China;
  • 4. Department of Health Service Management, China Medical University, Shenyang 110122, P. R. China;
HUI Wen, Email: huiwen@scu.edu.cn
Export PDF Favorites Scan Get Citation

The calculation of sample size is a critical component in the design phase of clinical trials incorporating health economic evaluations. A reasonable sample size is essential to ensure the scientific validity and accuracy of trial results. This paper summarizes the sample size calculation methods in the frequentist framework based on two health economic evaluation metrics: incremental cost-effectiveness ratio (ICER) and net benefit. It focuses on their applicable conditions, advantages, and limitations. The ICER method derives the sample size calculation formula by computing the ratio of incremental cost to incremental effect, while the net benefit method determines the economic viability of interventions by calculating incremental net benefit, subsequently leading to the formulation of the sample size calculation. Furthermore, this paper briefly discusses other sample size calculation methods, such as the classical Bayesian approach and the value of information analysis, providing a reference for calculating sample size in clinical trials with integrated health economic evaluations.

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved